We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Antibody Test Identifies Scleroderma Patients at High Risk for Pulmonary Hypertension

By LabMedica International staff writers
Posted on 02 May 2022

Scleroderma is caused by the immune system attacking the connective tissue under the skin and around internal organs and blood vessels. More...

This causes scarring and thickening of the tissue in these areas.

There are several different types of scleroderma that can vary in severity. Some types are relatively mild and may eventually improve on their own, while others can lead to severe and life-threatening problems. Detection of certain auto-antibodies flagged patients with scleroderma (also known as systemic sclerosis) who were especially likely to develop pulmonary hypertension over long-term follow-up, have been studied.

Clinical Immunologists at the University of Pittsburgh School of Medicine (Pittsburgh, PA, USA) performed a case-control study where cases were new anti-Th/To antibody (Laboratory Corporation of America, Burlington, NC, USA) positive referrals to Pittsburgh Scleroderma Center from 1980-2015. Controls were the next two consecutive anti-Th/To negative patients seen after a case. Long-term disease manifestations and survival were compared. The scientists identified 204 anti-Th/To positive systemic sclerosis (SSc) patients were and 408 controls. The mean age of the entire cohort was 52 ±12.9 years and 76% were female.

The scientists reported that Anti-Th/To positive patients more often presented without skin thickening and had higher rate of pulmonary hypertension (PH) and interstitial lung disease ILD than controls. They had less frequent muscle and joint involvement. After a median clinical follow-up of 6.1 years, 38% of Th/To patients had developed PH compared to 15% of other SSc patients. The rates of WHO Group 1 pulmonary arterial hypertension (PAH) were 23% in Th/To patients versus 9% in controls. After adjustment for age and gender, anti-Th/To antibody was associated with a 3.3 increased risk of developing PH at 10 years of follow-up from the first SSc center visit. Mortality was also higher in the antibody-positive patients.

The authors concluded that this was the largest cohort of anti-Th/To positive SSc patients with long-term follow-up data. The very high rate (38%) and associated independent risk of anti-Th/To patients developing PH in follow-up, particularly Group 1 PAH was particularly noteworthy. Patients presenting with limited skin involvement should be tested for Th/To antibody. If present, careful monitoring for PH is warranted. The study was published on April 25, 2022 in the journal Arthritis & Rheumatology.

Related Links:
University of Pittsburgh School of Medicine 
Laboratory Corporation of America 


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.